Abstract 1540P
Background
Neoadjuvant chemoradiotherapy (nCRT) is a standard treatment for resectable locally advanced oesophageal squamous cell carcinoma (ESCC); however, its effectiveness is curtailed by recurrence and distant metastasis. Developing novel therapies, such as combined checkpoint inhibitors, is crucial for improving patient survival. Tislelizumab, an anti-PD-1 monoclonal antibody, has shown promise in various malignancies. This is the first phase II study to assess the efficacy and safety of Tislelizumab combined with nCRT for resectable locally advanced ESCC.
Methods
All subjects underwent nCRT with a 40 Gy total radiation dose given daily for 5 days/week. Paclitaxel albumin (taxanes) with cisplatin/carboplatin were given on days 1 and 22, while Tislelizumab was administered twice on days 8 and 29 concurrently with radiation therapy. Finally, surgery was performed at 6-8 weeks post-treatment.
Results
By April 2023, 26 patients were enrolled in the study, with 21 undergoing surgical resection at a 100% R0 resection rate. Patients who received Tislelizumab combined with nCRT achieved a 100% objective remission rate, with 9 (42.8%) patients had complete response rate and 14 (66.6%) patients achieved major pathologic response, no surgical delay, among 6 patients continue to receive postoperative adjuvant therapy. Common side-effects included leukopenia, thrombocytopenia, neutropenia, anemia, anastomotic leakage, and rash. Most adverse events were grades 1/2, and grades 3/4 adverse events include four cases of grade 3 leukopenia, and one case of grade 3 neutropenia. Regrettably, 2 patients have passed away due to the novel coronavirus. The analysis of survival was immature, and patients are still being followed up.
Conclusions
Tislelizumab in combination with nCRT is a safe and effective treatment strategy for resectable locally advanced ESCC. The high complete response rate and favorable safety profile observed in this study warrant further investigation in larger, randomized controlled trials to confirm the benefit of Tislelizumab in improving treatment outcomes for patients with locally advanced ESCC.
Clinical trial identification
CTR2100051599.
Editorial acknowledgement
The drug was kindly provided by Beigene and Kelun.
Legal entity responsible for the study
The authors.
Funding
Clinical Research Incubation Project, West China Hospital, Sichuan University; Science and Technology Department of Sichuan Province; Beijing Medical Award Foundation; the 1·3·5 project for disciplines of excellence; National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21